CD13-specific Ligand Facilitates Xanthatin Nanomedicine Targeting Dendritic Cells for Therapy of Refractory Allergic Rhinitis

Publication date: Available online 25 January 2020Source: International Journal of PharmaceuticsAuthor(s): Xue Zheng, Chao Sun, Rilei Yu, Xin Chu, Jiahao Xu, Chengcheng Liu, Miaoqing Zhao, Xuelian Xu, Ming Xia, Cheng WangAbstractRelapse in Allergic Rhinitis (AR) is triggered by various unclear mechanisms. Xanthium strumarium L. as a traditional folk medicine can inhibit inflammatory responses through multiple mechanisms. Xanthatin (XT) is a bioactive compound derived from Xanthium strumarium L, and we developed a polymeric micelle (PM) that is dendritic cells (DCs)-specific targeting delivery system loading XT (NGR-XT-PM) based on a cyclic peptide moiety (NGR) to render DCs maturation-resistant for therapy of refractory AR. A murine model of AR was employed to investigate the in vivo therapeutic efficiency and relapse rate compared with the commercial product Budesonide. The results showed intranasal administration of NGR-XT-PM presented significant anti-allergy effect with no recurrence, in contrast, all mice treatment with Budesonide relapsed. NGR-XT-PM could effectively reverse the Th1/Th2 imbalance by depleting the serum inflammatory levels (IgE, histamine and IL-4) and DCs surface costimulatory molecules (CD80, CD86 and I-A/I-E), and promote immune tolerance by upregulating the level of Treg cells and reducing the levels of Th2, Th9 and Th17 cells. Furthermore, we appealed to virtual screening of inflammatory targets and found XT blocking the COX-2/PGE2 signaling pathway...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research